Clene Inc. (CLNN) 10% owner reports Symbiosis II LLC stock sales

Rhea-AI Filing Summary

Clene Inc. reported insider share sales by a 10% owner associated with Ugwumba Chidozie, disclosed in a Form 4 filing. The transactions involved indirect holdings of Clene common stock through Symbiosis II, LLC.

Symbiosis II, LLC sold 5,869 shares at $5.87 on January 5, 2026, 3,111 shares at $6.04 on January 6, 2026, and 3,938 shares at $6.29 on January 7, 2026. Following the last sale, Symbiosis II, LLC indirectly held 753,562 shares of Clene common stock.

Insider Trade Summary

Net Seller: 12,918 shares ($78,011)

Net Sell 3 txns

Insider Ugwumba Chidozie

Role 10% Owner

Sold 12,918 shs ($78K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,938	$6.29	$25K
Sale	Common Stock	3,111	$6.04	$19K
Sale	Common Stock	5,869	$5.87	$34K

Holdings After Transaction: Common Stock — 753,562 shares (Indirect, By Symbiosis II, LLC)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ugwumba Chidozie

(Last) (First) (Middle)

609 SW 8TH STREET

SUITE 510

(Street)

BENTONVILLE AR 72712

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clene Inc. [ CLNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S		5,869	D	$5.87	760,611	I	By Symbiosis II, LLC
Common Stock	01/06/2026		S		3,111	D	$6.04	757,500	I	By Symbiosis II, LLC
Common Stock	01/07/2026		S		3,938	D	$6.29	753,562	I	By Symbiosis II, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Chidozie Ugwumba	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who reported the insider transactions in Clene Inc. (CLNN)?

The Form 4 lists Ugwumba Chidozie as the reporting person and a 10% owner of Clene Inc., with the reported holdings held indirectly through Symbiosis II, LLC.

What type of Clene Inc. securities were involved in this Form 4?

The transactions involved Clene Inc. Common Stock, reported as non-derivative securities in Table I of the Form 4.

What insider sales of CLNN stock were reported on January 5–7, 2026?

Symbiosis II, LLC sold 5,869 Clene shares at $5.87 on January 5, 3,111 shares at $6.04 on January 6, and 3,938 shares at $6.29 on January 7, 2026.

How many Clene Inc. shares were indirectly owned after the reported transactions?

After the January 7, 2026 transaction, Symbiosis II, LLC indirectly held 753,562 shares of Clene Inc. common stock as reported in the Form 4.

Are the reported CLNN shares held directly by Ugwumba Chidozie?

No. The Form 4 shows the holdings as Indirect (I), with the nature of ownership listed as "By Symbiosis II, LLC" for each transaction.

Does this Clene Inc. Form 4 report any derivative securities?

No derivative securities are listed with transactions in Table II; the reported activity relates only to non-derivative common stock.